p38α MAPK signaling drives pharmacologically reversible brain and gastrointestinal phenotypes in the SERT Ala56 mouse

Matthew J. Robson,Meagan A. Quinlan,Kara Gross Margolis,Paula A. Gajewski-Kurdziel,Jeremy Veenstra-VanderWeele,Michael D. Gershon,D. Martin Watterson,Randy D. Blakely

DOI: https://doi.org/10.1073/pnas.1809137115

IF: 11.1

2018-10-08

Proceedings of the National Academy of Sciences

Abstract:Significance Autism spectrum disorder (ASD) is a neurodevelopmental disorder characterized by communication and social behavior deficits, repetitive behaviors, and medical comorbidities, including gastrointestinal dysfunction. No pharmacologic treatments are available that ameliorate core symptoms. Genetic variants in the serotonin transporter (SERT) are linked to ASD. Here we demonstrate that administration of a CNS-penetrant p38α MAPK antagonist normalizes multiple physiological and behavioral perturbations reminiscent of ASD in adult, SERT Ala56 mice. Conditional genetic manipulations validate a requirement for 5-HT neuron p38α MAPK signaling in establishing perturbations observed in SERT Ala56 mice. Our findings suggest that p38α MAPK may be a potential target for treatment of adults with ASD, particularly in relation to traits driven by elevated SERT activity and diminished 5-HT signaling.